SLU-PP-332 vs Triptorelin
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairFat Loss & Metabolic
SLU-PP-332Sexual Health & Libido
Triptorelin- Summary
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.
- Half-Life
- Not established in humans; rodent pharmacokinetics suggest hours
- Depot forms: weeks to months; aqueous: 6-8 hours
- Admin Route
- Oral (research), Subcutaneous (research)
- SubQ, IM
- Research
- —
- —
- Typical Dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- 100 mcg
- Frequency
- Once daily in rodent studies
- Single injection
- Key Benefits
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Rapid HPG axis restart after steroid use
- Single-injection PCT protocol possible
- Massively elevates LH and FSH via flare effect
- Restores endogenous testosterone faster than traditional PCT
- FDA-approved for established medical uses
- Side Effects
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Initial testosterone flare (intended)
- Injection site reactions
- Hot flashes (with chronic use)
- Decreased libido (chronic dosing)
- Stacks With
- —
- —